MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation.
Level 5 - mechanism / opinion, no new human data
Preclinical in vitro and animal research
PubMed 26147250 · doi:10.1038/ncb3195
What was done
Researchers investigated the mechanism by which MTOR inhibition via rapamycin modulates the senescence-associated secretory phenotype (SASP). They evaluated the expression and translation of cytokines (notably IL1A and IL6) and NF-κB transcriptional activity in senescent cells, and tested whether rapamycin could suppress the ability of senescent fibroblasts to stimulate prostate tumor growth in mice.
What was found
Rapamycin suppressed inflammatory cytokine secretion in senescent cells. It reduced IL6 and other cytokine mRNA levels while selectively suppressing the translation of membrane-bound IL1A, which in turn diminished NF-κB transcriptional activity. Exogenous IL1A restored IL6 secretion in rapamycin-treated cells. Additionally, rapamycin suppressed senescent fibroblast-stimulated prostate tumor growth in mice. The abstract reports no numerical values.
Why it matters
This study identifies a specific translational mechanism (IL1A-driven NF-κB activation) through which MTOR regulates SASP, providing a mechanistic basis for how rapamycin may reduce age-associated inflammation and late-life tumorigenesis.
Limits
The abstract provides no sample sizes, effect sizes, or statistical metrics. The findings are restricted to in vitro and mouse models, and clinical applicability in humans was not evaluated.
Cited by
- supports Dampening TOR activity with rapamycin suppresses primarily the inflammatory arm of the senescence-associated secretory phenotype (SASP).
- supports mTOR-dampening drugs suppress secretion in senescent cells rather than killing them, and the suppression lasts beyond drug application because it breaks a pro-inflammatory feedback loop that takes time to re-establish.